3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Head & Neck
1
Conditions
Thyroid Neoplasms
8
Hypothyroidism
6
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Sarcoma, Alveolar Soft Part
1
Recurrence
1
Postoperative Complications
1
Polycystic Ovary Syndrome
1
Neoplasms
1
Infertility, Female
1
Goiter
1
Fatigue
1
Depression
1
Brain Neoplasms
1
Anxiety Disorders
1
Advanced Differentiated Thyroid Gland Carcinoma
1
Interventions
Sorafenib
3
selpercatinib
2
cabozantinib
2
Thyroid (USP)
2
Sodium
2
Radiofrequency Ablation
2
Metformin
2
vandetanib
1
tomivosertib
1
temsirolimus
1
repotrectinib
1
pralsetinib
1
pembrolizumab
1
lenvatinib
1
binimetinib
1
apatinib
1
acetaminophen, codeine drug combination
1
Vitamin B 12
1
Tramadol
1
Thyroxine
1
Thyrotropin-Releasing Hormone
1
Technetium Tc 99m Sestamibi
1
Surgical Procedures, Operative
1
Pemetrexed
1
Panobinostat
1
Negative-Pressure Wound Therapy
1
NAc-Sar-Gly-Val-(d-allo-Ile)-Thr-Nva-Ile-Arg-ProNEt
1
Lysine Acetyltransferase 5
1
Iodine-131
1
Folic Acid
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Thyroid Diseases
×
Thyroxine
×
Clear all
NCT07239674
2025-11-20
DELTA
West China Hospital
Phase 3
Not yet recruiting
646 enrolled